News
TKL Research Risk-Based Monitoring Expert to Speak at DIA
(Rochelle Park, N.J.; May 19, 2015) — Lynn King, Senior Director of Clinical Monitoring at TKL Research, a full-service clinical research organization (CRO), will share her risk-based monitoring (RBM) knowledge at the Drug Information Association (DIA) 51st Annual Meeting in Washington, D.C., June 14-18. The forum, “Develop Risk-Based Monitoring Strategies to Innovate Study Oversight and Advance Study Execution,” will take place from 10:45 to 11:45 a.m. on Thursday, June 18.
The forum will explore a case study regarding development and implementation of an RBM strategy for a 30-site global Phase II atopic dermatitis trial. King will focus on the collaborative processes between the sponsor and the CRO.
“Sponsors are fortunate because regulatory agencies, such as the FDA, are beginning to accept newer, more efficient approaches, such as RBM,” King said. “Implementing an acceptable clinical monitoring plan, however, requires a thorough understanding of the new rules under which we’re operating.”
King will also chair the DIA workshop, “Develop Excellent Presentations to Innovate the Way You Communicate Information and Advance Your Career,” from 10:30 a.m. to 12:00 p.m. Wednesday, June 17.
A veteran research professional with more than 20 years of experience in drug development, King is a proven leader versed in hands-on monitoring and project management as well as coaching, mentoring and training in both CRO and pharmaceutical environments.
King will join other TKL experts at DIA and will be available to meet at the company’s exhibit at Booth 2202. Visit TKL at DIA and learn more about its capabilities at tklresearch.com.
About TKL Research, Inc.
TKL Research is a full-service, international CRO offering deep expertise in a full spectrum of dermatological indications as well as a complete range of clinical trial management services from Phase 1 to multicenter international studies. TKL’s emphasis on recruitment and site selection enables studies to be filled and initiated sooner, shortening timelines and reducing costs for a wide range of studies in dermatology and other therapeutic areas.
###